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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the effects of cytokines and growth factors for preventing oral mucositis in patients with cancer who are receiving treatment.
B A C K G R O U N D
Description of the condition
Treating cancer with chemotherapy, radiotherapy of the head
and neck, or targeted therapy can cause toxic oral side effects
(Al-Dasooqi 2013; Scully 2006; Sonis 2004). Perhaps the most
widely researched of these side effects is oral mucositis (Al-Dasooqi
2013), which affects at least 75% of high risk patients (those re-
ceiving head and neck radiotherapy or high-dose chemotherapy)
(Scully 2006). Oral mucositis may be under-reported in lower risk
groups for various reasons: their tendency to be outpatients with
less observation; less reporting of moderate mucositis; or patients
and clinicians wishing to avoid any disruption to optimal cancer
treatment (Scully 2006).
Simply put, oral mucositis affects the oral mucosa (the mucous
membrane ofmoist tissue lining the oral cavity) and can lead to the
development of lesions (ulcers). However, the process that leads to
oral mucositis is complex andmultifactorial, with Sonis’ five phase
model being the currently accepted explanation for the sequence
of events underlying the condition (Sonis 2004; Sonis 2009).
1. Initiation: DNA damage caused by chemotherapy or
radiotherapy results in the loss of ability to proliferate in the
basal cells of the epithelium (the external layers of cells lining the
oral mucosa). This produces reactive oxygen species (ROS).
2. Primary damage response: Radiotherapy, chemotherapy,
ROS, and DNA strand breaks all contribute to the activation of
transcription factors such as nuclear factor kappa beta (NF-Kβ),
and sphingomyelinases. All this leads to the upregulation of pro-
inflammatory cytokines (e.g. tumour necrosis factor alpha -
TNF-α), nitric oxide, ceramide, and matrix metalloproteinases,
resulting in the thinning of the epithelium through tissue injury
and cell death, culminating with the destruction of the oral
mucosa.
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3. Signal amplification: Some of the molecules in the previous
phase can lead to the exacerbation and prolonging of tissue
injury through positive or negative feedback (e.g. TNF-α can
positively feedback on NF-Kβ thus inducing more pro-
inflammatory cytokine production).
4. Ulceration: Bacteria colonise ulcers and their cell wall
products infiltrate the submucosa (the connective tissues beneath
the oral mucosa), activating tissue macrophages (white blood
cells that respond to infection or damaged/dead cells), which
results in further production of pro-inflammatory cytokines,
inflammation, and pain.
5. Healing: Signalling from the extracellular matrix of the
submucosa results in epithelial proliferation and differentiation,
and thus a thickening of the epithelium. The local oral flora are
reinstated.
Understanding of the pathobiology leading to mucosal toxicity as
a result of targeted therapies (e.g. mammalian target of rapamycin
(mTOR) inhibitor-associated stomatitis - mIAS) is currently lim-
ited, but it is thought to differ from chemotherapy- and radio-
therapy-induced mucositis, and the clinical presentation of the
ulcers is more similar to aphthous stomatitis (Al-Dasooqi 2013;
Boers-Doets 2013; Peterson 2015).
Chemotherapy-induced oral mucositis is regarded as an acute con-
dition, with ulceration normally occurring one week after treat-
ment, and resolving within three weeks of treatment (Sonis 2009).
Radiotherapy-induced oral mucositis is chronic in nature, with ul-
ceration normally occurring around two weeks into a seven-week
treatment cycle, and resolving three to four weeks after treatment
has ended (Sonis 2009).
Ulceration is the most significant phase as it leads to pain of vary-
ing severity, and difficulties with eating, swallowing, and talking
(Scully 2006). This in turn leads to the consumption of pain
relief medication, nutritional support (i.e. nasogastric or intra-
venous feeding), treatment of the oral mucositis, specialist oral
hygiene care, increased medical appointments and use of staff and
resources, and, in some instances, hospitalisation (Jensen 2014;
Miller 2001; Trotti 2003). Thus the negative impact on the qual-
ity of life of cancer patients, when they are already suffering, is
severe (Elting 2008; Epstein 1999). Further problems can occur in
immunosuppressed patients if whole bacteria on the ulcer surface
cross into the underlying submucosa, potentially leading to bac-
teraemia and sepsis, which require antibiotics and hospitalisation,
and can cause death (Jensen 2014; Peterson 2015; Scully 2006).
Therefore, oral mucositis can be a dose-limiting condition, dis-
rupting a patient’s optimal cancer treatment plan (Jensen 2014;
Peterson 2015; Sonis 2004). The additional costs associated with
oral mucositis are significant, with one study reporting a median
incremental cost ofUSD18,515per patient (Nonzee 2008). These
costs have been reported to be as much as USD 42,749 more per
patient when ulcerative oral mucositis is present (Sonis 2001).
Description of the intervention
As described above, oral mucositis occurs partly as result of the loss
of regenerative ability of the oral epithelial cells. Growth factors
and anti-inflammatory cytokines are used to counteract the biolog-
ical processes leading to this loss of proliferative ability.Growth fac-
tors and anti-inflammatory cytokines include (Raber-Durlacher
2013):
• keratinocyte growth factor;
• colony-stimulating factors;
• epidermal growth factor;
• transforming growth factor-beta;
• whey-derived growth factor;
• interleukin-11;
• ATL-104;
• trefoil factor.
How the intervention might work
The growth factors described here are proteins that bind to recep-
tors of target cells and either increase the proliferationof the epithe-
lial cells that form the mucous membrane lining of the oral cavity,
or promote the recovery of the white blood cells that contribute to
themaintenance of oral health following conventional or high dose
chemotherapy (with or without radiotherapy) (Raber-Durlacher
2013). Anti-inflammatory cytokines are also proteins or glycopro-
teins that bind to receptors of target cells, and are thought to al-
ter the complex balance of pro- and anti-inflammatory cytokines
involved in the pathogenesis of oral mucositis (Raber-Durlacher
2013).
Currently, evidence-based guidelines recommend growth factors
for the prevention of oral mucositis in patients with haematolog-
ical cancers undergoing high-dose chemotherapy and total body
irradiation prior to haematopoietic stem cell transplantation (Lalla
2008). It has been postulated that tumour cells may also have
receptors accommodating cytokines and growth factors, thus en-
couraging the proliferation of cancer cells in solid tumours (Lalla
2008; von Bültzingslöwen 2006). A 2010 systematic review sug-
gested that the risk of acutemyeloid leukemia (AML) ormyelodys-
plastic syndrome (MDS) is increased in people with various can-
cers receiving chemotherapy with granulocyte colony-stimulating
factor (G-CSF) when compared to those receiving chemotherapy
without G-CSF (Lyman 2010). The authors concluded that it was
not clear whether the increased AML/MDS risk was due to G-
CSF or due to the increased chemotherapy dose-intensity in those
patients. However, the review also reported a reduction in overall
mortality for those receiving G-CSF.
As there is currently no clear consensus on this issue, the use of
cytokines and growth factors for the prevention of oral mucositis
is not limited to haematological cancer patients in practice.
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Why it is important to do this review
This review is part of a series that will replace the previously pub-
lished Cochrane review covering all interventions for the preven-
tion of oral mucositis in patients with cancer receiving treatment
(Worthington 2011). The Mucositis Study Group (MSG) of the
Multinational Association of Supportive Care in Cancer/Interna-
tional Society of Oral Oncology (MASCC/ISOO) is a group that
was set up in 1998 for the purpose of producing international
evidence-based clinical practice guidelines for managing mucosi-
tis (both oral and gastrointestinal), which they first published in
2004, with the latest update published in 2014 (Lalla 2014). In
order to facilitate the future updating of Cochrane reviews on this
topic, and also to make them more usable to clinicians, guideline
developers, and consumers, we have decided to divide the original
Cochrane review into the same intervention categories as those
used by MASCC/ISOO, which are as follows:
• basic oral care/good clinical practice;
• growth factors and cytokines;
• anti-inflammatory agents;
• antimicrobials, mucosal coating agents, anaesthetics, and
analgesics;
• laser and other light therapy;
• cryotherapy;
• natural and miscellaneous agents.
We believe that following theMASCC/ISOO structure will better
enable the Cochrane reviews to feed into such guidelines. We
can also be more thorough and rigorous in our assessment and
summarising of the evidence in each of the categories, which was
not feasible in a single Cochrane review approaching 150 included
studies.
It is also important to do this review as it is consistently shown to
be the most used review produced by the Cochrane Oral Health
Group (in terms of full-text downloads). It was also ranked by an
expert panel of oral medicine specialists as being the most impor-
tant topic in the field of oral medicine in an international priori-
tisation exercise carried out by the Cochrane Oral Health Group
in 2014 (Worthington 2015).
O B J E C T I V E S
To assess the effects of cytokines and growth factors for preventing
oral mucositis in patients with cancer who are receiving treatment.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include all randomised controlled trials (RCTs) of parallel
design. It is possible to conduct cross-over studies in this area as
patients may receive several treatment sessions/cycles, with any
mucositis completely healing in the periods between the sessions.
However, wewill not include cross-over data as we cannot discount
any period effects, withmucositis risk increasing as patients receive
further cycles of treatment (Scully 2006; Sonis 2009). Instead, we
will use the first-period data only and treat such studies as parallel
studies.
Types of participants
We will include all patients with cancer who are receiving treat-
ment.
Types of interventions
We will include studies comparing growth factors and cytokines
for the prevention of oral mucositis (we will also include targeted
therapy-induced stomatitis) against usual care, no treatment, or
any other treatment to prevent oral mucositis. We will also include
studies comparing different growth factors and cytokines or dif-
ferent regimens of growth factors and cytokines against each other
(head-to-head studies).
We will exclude studies with ’complex’ interventions for the pre-
vention of mucositis, such as lasers plus growth factors and cy-
tokines versus lasers. We will exclude studies assessing different
cancer treatments where the primary outcome is survival/cure,
with mucositis as a toxicity.
Types of outcome measures
We are in agreement with Williamson 2012 that, if clinical trials
and systematic reviews are to be utilised, the outcomes assessed
should be those considered important to patients, healthcare pro-
fessionals, and other key stakeholders. If outcomes and outcome
measures are inconsistent across studies, it will not be possible to
compare and summarise research, and there is potential for out-
come reporting bias, with the selective reporting of results based
on statistical significance and favourability (Clarke 2007; Dwan
2008; Williamson 2005). This can lead to exaggerated estimates
of effect in systematic reviews of interventions, leading to an in-
correct belief that an intervention is more beneficial that it truly is
(Clarke 2007). It is thought that the way to address this problem
is to develop disease- or condition-specific core outcome sets to be
used as a minimum when conducting and reporting clinical trials
(Clarke 2007; Williamson 2012).
Therefore we will use the core outcome set produced by Bellm
2002, which is registered on the COMET (Core Outcome Mea-
sures in Effectiveness Trials) Initiative’s website (www.comet-
initiative.org), and is the only core outcome set for oral mucositis
known to us.
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Primary outcomes
Mucositis (at all levels of severity) using an appropriate, objective
scale. We will use mucositis measured on a 0 to 4 point scale
(none to severe) and dichotomise it as any mucositis (0 versus
1+), moderate to severe mucositis (0 to 1 versus 2+), and severe
mucositis (0 to 2 versus 3+).
Some studies measure mucositis using a composite scale. If it is
possible to extract the ’mucositis only’ data from the total score,
we will include the data in the analyses. If it is not possible, we
will record the composite data in an additional table.
Secondary outcomes
• Interruptions to cancer treatment.
• Oral pain.
• Quality of life.
• Normalcy of diet (including use of percutaneous
endoscopic gastrostomy (PEG) feeding tubes or total parenteral
nutrition (TPN)).
• Adverse events.
• Number of days in hospital.
• Number of days of treatment with opioid analgesics.
• Number of days unable to take medicine orally.
Search methods for identification of studies
For the identification of studies included or considered for this re-
view, we will develop detailed search strategies. These will be based
on the search strategy forMEDLINE (Ovid) (Appendix 1), which
will be revised appropriately for each database. The MEDLINE
search strategy has a combination of controlled vocabulary and
free text terms and will be linked with the Cochrane Highly Sen-
sitive Search Strategy (CHSSS) for identifying randomised trials
(RCTs) in MEDLINE: sensitivity maximising version (2008 revi-
sion) as referenced in Chapter 6.4.11.1 and detailed in box 6.4.c
of the Cochrane Handbook for Systematic Reviews of Interventions
Version 5.1.0 (updated March 2011) (Higgins 2011).
Due to the Cochrane Embase Project to identify all clinical tri-
als on the database and add them to CENTRAL, only the last
six months of the Embase database will be searched. Please see
the searching page on the Cochrane OHG website for more in-
formation. No other restrictions will be placed on the language or
date of publication when searching the electronic databases.
Electronic searches
We will search the following electronic databases:
• the Cochrane Oral Health Group Trials Register (to date);
• the Cochrane Central Register of Controlled Trials
(CENTRAL; current issue);
• MEDLINE via Ovid (1946 to date) (Appendix 1);
• Embase via Ovid (six months previous to date);
• CANCERLIT via PubMed (1950 to date);
• CINAHL via EBSCO (1937 to date).
Searching other resources
We will search the following databases for ongoing trials:
• US National Institutes of Health Trials Registry (
clinicaltrials.gov) (to date);
• World Health Organization (WHO) International Clinical
Trials Registry Platform (apps.who.int/trialsearch/default.aspx)
(to date).
We will only include handsearching done as part of the Cochrane
Worldwide Handsearching Programme and uploaded to CEN-
TRAL.
Data collection and analysis
Selection of studies
Two review authors will independently screen the titles and ab-
stracts retrieved from the electronic searches. We will obtain full
text copies of all studies that appear to meet the inclusion criteria
of the review, or where there is insufficient information in the title
or abstract to make a clear judgement. Two review authors will
independently assess the full text copies for eligibility and attempt
to resolve any disagreements through discussion. We will consult
a third review author if we are unable to resolve disagreements.
On assessing the full text article, we will discard any studies that
clearly do not meet the inclusion criteria. We will record all other
studies that do not meet the inclusion criteria, along with reasons
for exclusion, in the ’Characteristics of excluded studies’ table.
Data extraction and management
Two review authors will independently extract the data from each
included study using a specially designed data extraction form,
which will first be piloted on a small sample of studies. We will
contact study authors for clarification or missing data where nec-
essary and feasible. We will resolve any disagreements through
discussion, consulting a third review author to achieve consensus
when necessary.
We will record the following data for each included study in the
’Characteristics of included studies’ table.
• Trial design, location, number of centres, recruitment
period.
• Inclusion/exclusion criteria, age and gender of participants,
number randomised/analysed, any other potentially important
prognostic factors (e.g. cancer type, cancer treatment, etc.).
• Detailed description of the intervention and comparator,
including timing and duration. Information on compliance with
the intervention.
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• Details of the outcomes reported, including method of
assessment and time(s) assessed.
• Details of sample size calculations, adverse effects, funding
sources, declarations/conflicts of interest.
Assessment of risk of bias in included studies
Two review authors will independently assess the risk of bias of
each included study using the Cochrane domain-based, two-part
tool as described in Chapter 8 of the Cochrane Handbook for Sys-
tematic Reviews of Interventions (Higgins 2011). We will contact
study authors for clarification or missing information where nec-
essary and feasible. We will resolve any disagreements through
discussion, consulting a third review author to achieve consensus
when necessary.
We will complete a ’Risk of bias’ table for each included study. For
each domain of risk of bias, wewill first describe what was reported
to have happened in the study. This will provide the rationale for
our judgement of whether that domain is at low, high, or unclear
risk of bias.
We will assess the following domains:
1. sequence generation (selection bias);
2. allocation concealment (selection bias);
3. blinding of participants and personnel (performance bias);
4. blinding of outcome assessment (detection bias);
5. incomplete outcome data (attrition bias);
6. selective outcome reporting (reporting bias);
7. other bias.
We will categorise the overall risk of bias of individual studies.
Studies will be categorised as being at low, high, or unclear risk of
bias according to the following criteria:
• low risk of bias (plausible bias unlikely to seriously alter the
results) if all domains are at low risk of bias;
• high risk of bias (plausible bias that seriously weakens
confidence in the results) if one or more domains are at high risk
of bias; or
• unclear risk of bias (plausible bias that raises some doubt
about the results) if one or more domains are at unclear risk of
bias.
We will also present the ’Risk of bias’ summary graphically.
Measures of treatment effect
For continuous outcomes (e.g. oral pain on a visual analogue scale)
where studies use the same scale, we will use the mean values
and standard deviations (SDs) reported in the studies in order
to express the estimate of effect as mean difference (MD) with
95% confidence interval (CI). Where different scales are used, we
will consider expressing the treatment effect as standardised mean
difference (SMD) with 95% CI.
For dichotomous outcomes (e.g. mucositis of any severity/no mu-
cositis), we will express the estimate of effect as a risk ratio (RR)
with 95% CI.
Unit of analysis issues
The participant will be the unit of analysis.
Dealing with missing data
We will attempt to contact the author(s) of all included studies,
where feasible, for clarification, missing data, and details of any
other outcomes that may have been measured but not reported.
Wewill use themethods described in Section 7.7.3 of theCochrane
Handbook for Systematic Reviews of Interventions to estimate miss-
ing SDs (Higgins 2011).Wewill not use any other statistical meth-
ods or perform any further imputation to account formissing data.
Assessment of heterogeneity
If a sufficient number of studies are included in any meta-anal-
yses, we will assess clinical heterogeneity by examining the char-
acteristics of the studies, the similarity between the types of par-
ticipants, the interventions, and the outcomes. We will also assess
heterogeneity statistically using a Chi² test, where a P value < 0.1
indicates statistically significant heterogeneity. We will quantify
heterogeneity using the I² statistic. A guide to interpretation of
the I² statistic given in Section 9.5.2 of the Cochrane Handbook
for Systematic Reviews of Interventions is as follows (Higgins 2011):
• 0% to 40%: might not be important;
• 30% to 60%: may represent moderate heterogeneity;
• 50% to 90%: may represent substantial heterogeneity;
• 75% to 100%: considerable heterogeneity.
Assessment of reporting biases
If at least 10 studies are included in a meta-analysis, we will assess
publication bias according to the recommendations on testing for
funnel plot asymmetry (Egger 1997), as described in Section 10.4
of the Cochrane Handbook for Systematic Reviews of Interventions (
Higgins 2011). If asymmetry is identified,wewill examine possible
causes.
Data synthesis
We will only carry out meta-analyses where there are studies of
similar comparisons reporting the same outcomes. We will com-
bine MDs for continuous data, and RRs for dichotomous data.
Our general approach will be to use a random-effects model. With
this approach, the CIs for the average intervention effect will be
wider than those that would be obtained using a fixed-effect ap-
proach, leading to a more conservative interpretation.
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We will use an additional table to report the results from studies
not suitable for inclusion in a meta-analysis.
Subgroup analysis and investigation of heterogeneity
We will carry out subgroup analyses according to type of cancer
treatment and age group (children versus adults).
Sensitivity analysis
We will test the robustness of our results by performing sensitivity
analyses based on excluding the studies at unclear or high risk of
bias from the analyses.
If any meta-analyses include several small studies and a single very
large study, we will undertake a sensitivity analysis comparing the
effect estimates from both random-effects and fixed-effect models.
If these are different we will report on both analyses as part of the
results section, and we will consider possible interpretation.
Presentation of main results
Wewill produce a ’Summary of findings’ table for each comparison
that includes more than one study, and for the main outcomes
(listed below).Wewill useGRADEmethods (GRADE 2004), and
the GRADEpro online tool for developing ’Summary of findings’
tables (www.guidelinedevelopment.org).We will assess the quality
of the body of evidence for each comparison and outcome by
considering the overall risk of bias of the included studies, the
directness of the evidence, the inconsistency of the results, the
precision of the estimates, and the risk of publication bias. We will
categorise the quality of each body of evidence as high, moderate,
low, or very low.
Main outcomes:
• mucositis incidence;
• interruptions to cancer treatment;
• oral pain;
• quality of life;
• normalcy of diet;
• adverse events;
• number of days in hospital.
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A P P E N D I C E S
Appendix 1. MEDLINE (Ovid) search strategy
1. exp NEOPLASMS/
2. exp RADIOTHERAPY/
3. exp Antineoplastic agents/
4. Anti-neoplastic combined chemotherapy protocols/
5. Bone Marrow Transplantation/
6. Hematopoietic Stem Cell Transplantation/
7. (neoplasm$or cancer$ or leukaemi$or leukemi$ or tumour$ or tumor$ ormalignan$ or neutropeni$ or carcino$ or adenocarcinoma$
or lymphoma$).ti,ab.
8. (radioth$ or radiat$ or irradiat$).ti,ab.
9. ((bone adj marrow adj5 transplant$) or “hematopoietic stem cell transplant$” or “haematopoietic stem cell transplant$” or
HSCT).ti,ab.
10. chemo$.ti,ab.
11. or/1-10
12. exp STOMATITIS/
13. Candidiasis, Oral/
14. stomatitis.ti,ab.
15. mucositis.ti,ab.
16. (oral adj6 mucos$).ti,ab.
17. (mycosis or mycotic).ti,ab.
18. mIAS.ti,ab.
19. or/12-18
20. ((growth adj factor$) or (growth adj substance$) or (immunologic adj factor$)).ti,ab.
21. Fibroblast growth factor 7/
22. “fibroblast growth factor$”.ti,ab.
23. (keratinocyte$ or cytokine$).ti,ab.
24. (palifermin$ or KGF or FGF).ti,ab.
25. (kepivance or velafermin or repifermin).ti,ab.
26. glycoprotein$.ti,ab.
27. exp Colony-stimulating factors/
28. (“colony-stimulat$” or “macrophage-granulocyte inducer$” or “myeloid cell-growth inducer$” or “protein inducer MGI”).ti,ab.
29. (GM-CSF or G-CSF).ti,ab.
30. (molgramostim or Growgen-GM or Leucomax or Molcass or Gramostim or Leucocitim or Mielogen or Meustim or Bagomol or
Gramal).ti,ab.
31. Epidermal growth factor/
32. (rhEGF or “recombinant epithelial growth factor$” or “epidermal growth factor$” or EGF).ti,ab.
33. Platelet-derived growth factor/
34. (“platelet-derived growth factor$” or PDGF or “platelet lysate”).ti,ab.
35. Transforming Growth Factor beta/
36. (“transforming growth factor$” or “bone-derived transforming growth factor$” or “milk growth factor$” or “platelet transforming
growth factor” or TGF-beta or TGFbeta).ti,ab.
37. Hepatocyte growth factor/
38. (“hepatocyte growth factor$” or hepatopoietin or “scatter factor”).ti,ab.
39. exp Somatomedin/
40. (somatomedin$ or “insulin-like growth factor$” or “sulfation factor” or Mecasermin or Increlex or Iplex or IGF-1 or IGF1).ti,ab.
41. erythropoietin$.ti,ab.
42. Thrombopoietin/
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43. (thrombopoietin$ or “mpl Ligand” or “megakaryocyte colony stimulating factor$” or “megakaryocyte growth and development
factor$” or “MGDF factor” or “myeloproliferative leukemia virus oncogene ligand” or “thrombocytopoiesis-stimulating factor” or
thrombocytopoietin$).ti,ab.
44. Ghrelin/
45. Interleukin 11/
46. (“interleukin 11” or “Adipogenesis Inhibitory Factor$” or IL-11 or IL11).ti,ab.
47. (ghrelin$ or “GHRL protein” or obestatin).ti,ab.
48. (ATL-104 or ATL104).ti,ab.
49. (whey or (“milk derived” adj (protein or growth factor))).ti,ab.
50. Glucagon-Like Peptide 2/
51. (“glucagon-like peptide 2” or (amino adj acid$) or proglucagon or GLP-2 or teduglutide or Gattex or Revestive).ti,ab.
52. Glutathione/
53. (“trefoil factor” or “carcinoembryonic antigen cell adhesion molecule 1” or glutathione or isethion).ti,ab.
54. Vascular endothelial growth factors/
55. (“vascular endothelial growth factor$” or VEGF$).ti,ab.
56. Molecular targeted therapy/
57. (targeted adj3 (therap$ or agent$)).ti,ab.
58. (biologic$ adj therap$).ti,ab.
59. or/20-58
60. 11 and 19 and 59
The above subject search will be linked to the Cochrane Highly Sensitive Search Strategy (CHSSS) for identifying randomised trials in
MEDLINE: sensitivity maximising version (2008 revision) as referenced in Chapter 6.4.11.1 and detailed in box 6.4.c of theCochrane
Handbook for Systematic Reviews of Interventions, Version 5.1.0 [updated March 2011] (Higgins 2011).
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized.ab.
4. placebo.ab.
5. drug therapy.fs.
6. randomly.ab.
7. trial.ab.
8. groups.ab.
9. or/1-8
10. exp animals/ not humans.sh.
11. 9 not 10
WH A T ’ S N E W
Date Event Description
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